Clinical Trial

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 25, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
An open, non-randomized Phase I trial of dose-escalation and cohorts expansion to evaluate the safety, pharmacokinetic profile and initial efficacy of APG-115 alone or in combination with APG-2575 in the treatment of recurrent or refractory pediatric neuroblastoma or solid tumors.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-01-18; most recent amendment 2025-02-24.
Status change: Not Yet Recruiting → Recruiting 2023-03-23
Trial Details
NCT Number NCT05701306
Lead Sponsor Ascentage Pharma Group Inc.
Collaborators: Suzhou Yasheng Pharmaceutical Co., Ltd.
Conditions Neuroblastoma, Solid Tumor
Enrollment 100 participants
Start Date 2023-02-28
Primary Completion 2026-06-01 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-25